The inquiry centers on the company’s September 8, 2026, announcement concerning Phase 1/2 trial data for BEAM-302, a treatment for alpha-1 antitrypsin deficiency. While Beam Therapeutics reported that the single-dose treatment maintained an acceptable safety profile, the disclosure revealed transient Grade 1 elevations in alanine transaminase and aspartate aminotransferase levels among participants. Investors reacted sharply to the news, driving the company’s stock price down by 9.54%, or $2.83 per share, to close at $26.83.
In section Releases
Pomerantz LLP Launches Investigation into Beam Therapeutics
The New York-based Pomerantz Law Firm has initiated an investigation into Beam Therapeutics following a September stock decline triggered by clinical trial disclosures. Legal counsel is currently examining whether the company or its leadership engaged in securities fraud or unlawful business practices regarding the development of the BEAM-302 candidate.
Pomerantz LLP, a firm specializing in securities class litigation, is now soliciting contact from shareholders affected by the recent price volatility. The firm, which maintains an international presence across six global cities, aims to determine if the clinical trial reporting constitutes a breach of fiduciary duty or corporate misconduct.
Comments (0)
No comments yet. Be the first!